CardioGenics Holdings, developer for the In-Vitro-Diagnostics (“IVD”) testing market, announced that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics’ proprietary self-metering cartridges for its QL Care analyzer. The term of the agreement is three years and the purchase price for each cartridge shall be as specified in each purchase order issued pursuant to the agreement.
CardioGenics’ self-metering cartridge is a disposable pre-loaded test cartridge that allows the QL Care analyzer to analyze blood samples without the need for an independent metering mechanism, as the cartridge automatically deposits an accurate amount of whole blood necessary for each test into the cartridge’s reaction chamber. This allows the QL Care analyzer to provide at the point-of-care quantitative test results of laboratory quality. Point-of-care analyzers that do not utilize self-metering cartridges must instead utilize manual metering of the blood samples or rely on passive fluid movements, both of which are time-consuming, sometimes inaccurate and add to testing costs.
The self-metering cartridge will be used for all tests on the QL Care analyzer, including the company’s upcoming Troponin-I test, which addresses a $600 million testing market, as well as the company’s planned heart failure tests, which address a $1 billion testing market.
“We are very pleased that Plasticap will be a manufacturer of the self-metering cartridge for our QL Care analyzer,” said Dr. Yahia Gawad, CEO of CardioGenics. “Plasticap has excellent precision manufacturing capabilities and we look forward to working with them.”